The role of GLP-1 receptor agonists in managing type 2 diabetes.
Where this comes from
- Record sourced from PubMed, PMID 35914933.
- Also identified by DOI 10.3949/ccjm.89a.21110.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control in patients with type 2 diabetes mellitus, have cardioprotective and renoprotective effects, and do not cause weight gain or significant hypoglycemia. In fact, they have been found to be effective for weight loss in patients with obesity with and without diabetes. They are now the preferred drugs to add to the regimen when oral metformin by itself is not enough to meet the patient's hemoglobin A1c goal.
Medical subject headings
- Diabetes Mellitus, Type 2
- Hypoglycemia